The post-pandemic belief that CDMOs would retain lasting pricing power has faded. The discussion at a major healthcare industry forum was notably more sober: capital is now flowing toward assets with proven execution and measurable ROI, and large pharma is reframing manufacturing as a capital allocation choice rather than a capability badge. The tone across recent industry recaps was one of selective optimism, cost of capital awareness, and a premium on reliable delivery over greenfield promises. In other words, sponsors still need external capacity, but they are narrowing the selection to proven partners.
This shift is not happening in a vacuum. U.S. policy is reinforcing the logic behind supply chain resilience. An intense reshoring push, mixing threatened pharma specific trade measures, streamlined domestic permitting, and political activity around essential medicines, is catalysing unprecedented onshore announcements by major sponsors, led by large scale multi site build outs. The net effect is not autarchy; it is targeted regionalisation that reshapes sponsor sourcing criteria and privileges CDMOs with credible US footprints, inspection histories, and balance sheets robust enough to invest through cycles.
Demand drivers: real, but conditional
At successive industry gatherings, the message was consistent: funding has stabilised off prior lows, and late stage pipelines are grinding back, yet sponsors are discriminating about whom they trust with scale up. Early stage program counts are still below pre-pandemic levels, and buyers are consolidating work with fewer CDMOs that can evidence execution and quality. The growth story is intact in biologics, sterile injectables, complex conjugates, and selected high potency APIs, but the bar for operational maturity has risen materially.
Reshoring is no longer rhetorical; it is operational. Large sponsor announcements of domestic programs spanning APIs and parenterals, plus new sites across multiple regions, are emblematic of a broader sponsor calculus that weighs trade risk, demand volatility, and regulatory proximity against labor scarcity and capital intensity. For CDMOs, the implication is stark: a US presence is no longer a marketing line; it is often a gating requirement for strategic categories and dual sourcing strategies.
Modality complexity: bifurcation, not uniform insourcing
The growth edge is still where process complexity and variability challenge in house models. Industry reporting and biologics CDMO market updates point to sustained expansion in biologics drug substance and drug product, with fill finish remaining structurally tight in critical subsegments even as some pandemic era bottlenecks unwind. Sponsors increasingly want integrated development to DP offerings and tech transfer fluency, especially for fragile biologics and late line oncology. The pattern: platform core steps may stay internal; peripheral, scalable, or redundancy capacity migrates to trusted partners with rigorous PQS and digital quality capabilities.
Within advanced modalities, the picture is uneven. Capacity that was rushed into existence during recent cycles now faces patchy utilisation as clinical timelines and reimbursement realities bite; industry leaders have called for a reset in advanced therapy CDMO models, emphasising digital maturity and economic realism over reservation fee driven capacity theater, for example, symbolic capacity that looks impressive on paper but lacks operational substance. That said, late stage vector and allogeneic pipelines have not disappeared; they are consolidating with better capitalized providers, making partner selection a decisive strategic factor.
Certain conjugated modalities are the counter example: momentum continues to build, with multiple observers flagging double digit growth in outsourced conjugation, payload supply, and high containment manufacturing. As recent approvals and pipelines expand into solid tumors and beyond, payload and linker supply chains are becoming strategic bottlenecks, advantaging CDMOs that can integrate biologics, potent chemistry, conjugation, and aseptic DP under one validated governance model.
Capacity and pricing: from scarcity premium to reliability premium
The latent overcapacity risk that many flagged earlier is visible in selective pockets: early stage advanced therapy suites, undifferentiated biologics bioreactors, and parts of generic sterile injectables. The industry speaks of a post boom hangover: assets built for a funding cycle rather than a utilisation frontier.
Yet this is not an across the board glut. Fill finish for complex biologics remains investment heavy and operationally scarce in certain formats; equipment lead times, experienced aseptic talent, and validation throughput continue to constrain ramp speed. Sponsors have responded by concentrating work with fewer, demonstrably reliable partners and demanding price discipline and co investment where appropriate.
The practical translation of power back to pharma is not simply price cuts; it is tighter tech transfer gates, more onerous quality expectations, and contractual structures that shift more risk to the CDMO when capacity is speculative. The real business gets done in side rooms with CMC and C suite buyers who are not swayed by capability brochures but by audit history, right first time metrics, and realistic slot to batch glidepaths.
Regulatory climate: scrutiny up, patience down
Inspection and enforcement data through recent cycles corroborate what sponsors already internalized: compliance risk is rising. Multiple analyses point to higher volumes of warning actions, a resurgence of in person and unannounced inspections, including abroad, and sharper focus on data integrity and sterility assurance. For CDMOs, the penalty for learning on the client molecule has never been higher, and the premium on robust PQS, electronic batch records, and inspection ready documentation is now table stakes.
What this means for CDMO strategy beyond slogans
Specialists can thrive, but only if they are genuinely world class. In complex conjugates, that means high containment that works under commercial cadence, analytics that ensure consistency, and locked down payload supply. In advanced therapies, it means digitized batch genealogy, closed system expertise, and realistic cost to serve models that withstand payer scrutiny. The risk is modality cyclicality and customer concentration; the mitigation is to anchor around platform technologies where the CDMO is an extension of the sponsor core, not a generic slot. Recent market work underscores that sponsors will pay a reliability premium for such specialization when it compresses time to first in human or de risks regulatory readiness.
End to end models remain attractive to venture backed developers and mid cap sponsors, but execution complexity is punishing. Integration works only when program management, digital QMS, and late phase quality systems are strong across the chain. The old one stop shop narrative now has to be backed by cross site deviation management, tech transfer toolkits, and site to site process equivalence that survive regulatory daylight. Otherwise, sponsors will unbundle to best in class nodes.
Scaled reliability providers can succeed in the new price discipline if they obsess over lean operations, inspection history, and conservative capital allocation. With domestic resilience requirements rising, these players can capture mature product transfers and lifecycle volumes, but only by proving that cost competitiveness and deviation performance are durable. The reshoring wave opens doors for such work, yet talent scarcity and validation lead times argue for automation, digital twins, and predictive maintenance to defend margins.
Equally important is what to avoid. The most dangerous posture in the current cycle is capacity first, value later: undifferentiated expansion and modality tourism are leading causes of distress. Build and pray approaches, especially in sterile injectables without isolator mastery or in advanced therapies without closed system competence, invite quality failures just as regulatory scrutiny rises. The winners are those who invest last and smartest, not first and fastest.
The sponsor CDMO contract: asymmetry by design, partnership by proof
Sponsors are not looking for vendors. They are looking for execution partners who absorb volatility without amplifying it. There are a few non negotiables: risk based planning, alternate sourcing designed into programs, digitised quality, and credible surge capacity. But the quid pro quo is real: no guaranteed volumes for promises; only for performance. The CDMO business model in the current cycle is structurally more risk bearing, and the firms that internalise that reality, financially and operationally, will outlast the cycle.
A realistic outlook for the next cycle
Three forces will define the next planning horizon.
First, policy driven regionalization will continue to channel demand toward domestically capable networks, particularly for biologics, demand sensitive modalities, critical injectables, and select APIs.
Second, modality complexity will keep bifurcating work: platform adjacent steps may stay in house, but high skill or redundancy work will flow to CDMOs that function as platform extensions, not transactional capacity.
Third, regulatory intensity will keep compressing the tolerance for learning, driving sponsors to concentrate spend with partners who have inspection ready systems and demonstrated tech transfer proficiency.
Against that backdrop, a practical positioning playbook emerges. Specialists should double down on the two to three choke points in their chosen modality where they can be unequivocally best in class and price for reliability. End to end providers must invest as much in program orchestration and digital quality as in steel and bioreactors, because the differentiator is the frictionless hand off across their own sites. Reliability providers should align with the reshoring agenda by automating aggressively, demonstrating regulator tested systems, and offering transparent, data rich performance dashboards that make procurement decisions easier. All archetypes should adopt ruthless capital discipline: build only where there is line of sight to risk-adjusted utilisation, co-invest with anchor customers, and sequence capacity with commissioning and PQS maturity, not just construction milestones.
It is tempting to romanticise the growth curve, but a more realistic, skeptical stance is warranted. Demand is real, but conditional. Growth exists, but it is polarised. The relationship with pharma is asymmetric by design, but partnership by proof is possible. The CDMOs that matter three years from now will not be the ones that believed most in the story; they will be the ones whose governance, digital backbone, inspection record, and capital choices allowed them to survive its consequences. That is the new definition of strategic infrastructure.
